MaxCyte, Inc. (NASDAQ:MXCT)
| Market Cap | 133.90M-24.2% |
| Revenue (ttm) | 31.05M-13.2% |
| Net Income | -35.64M+20.4% |
| EPS | -0.33+22.3% |
| Shares Out | 107.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,588,979 |
| Open | 1.23 |
| Previous Close | 0.96 |
| Day's Range | 1.08 - 1.33 |
| 52-Week Range | 0.64 - 1.87 |
| Beta | 1.49 |
| Analysts | Buy |
| Price Target | 6.00(+380.00%) |
| Earnings Date | Nov 11, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About MXCT
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$MXCT stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in MXCT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MXCT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MXCT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
MXCT Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Revenue from Contracts with Customers | $4.94M | 40.44% |
| Product sales | $4.10M | 33.57% |
| Revenue from Lease Elements | $2.33M | 19.13% |
| Assay and other service revenue | $583.00K | 4.78% |
| Licenses | $255.00K | 2.09% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New MXCT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MXCT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MXCT
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $3.54M |
| VXFVanguard Extended Market ETF | $1.57M |
| VHTVanguard Health Care ETF | $366.59K |
| BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | $60.00K |
Estimated from each fund’s disclosed top holdings × AUM
MXCT Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from MXCT’s recent data — informational, not investment advice